樂觀
$24.00
情境價格
$11.370
+0.230 (+2.02%)收盤時
Cellebrite DI Ltd is an Israel-based company engaged primarily in the software sector. The Company is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The Company provides solutions for the public and private sectors, enabling organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. The Company's platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. The Company aims to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world.
Cellebrite DI Ltd is not a strong buy right now due to its current price of $11.03, which is significantly below the average analyst price target of $20. However, the stock has shown a 21% year-over-year growth in annual recurring revenue, indicating potential for recovery. The main risk is the recent earnings miss with an EPS surprise of -44.44%, suggesting that the company's financial performance may not meet investor expectations in the near term.
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Cellebrite to Report Q3 2026 Financial Results on November 12

Cellebrite to Release Q3 2026 Financial Results on November 12

Cellebrite to Release Q3 2026 Financial Results

Cellebrite to Release Q3 2026 Financial Results on November 12

Stocks Investors Should Consider Selling Now
Cellebrite DI Ltd is an Israel-based company engaged primarily in the software sector. The Company is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The Company provides solutions for the public and private sectors, enabling organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. The Company's platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. The Company aims to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. It operates in the Technology sector.
Cellebrite DI Ltd is not a strong buy right now due to its current price of $11.03, which is significantly below the average analyst price target of $20. However, the stock has shown a 21% year-over-year growth in annual recurring revenue, indicating potential for recovery. The main risk is the recent earnings miss with an EPS surprise of -44.44%, suggesting that the company's financial performance may not meet investor expectations in the near term.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。